GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
London, UK; 18 September 2013: GW Pharmaceuticals plc (GWPH) announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.